Illumina Inc. (NASDAQ: ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the T...
Supported by recent clinical data from the first-ever clinical study of an oral dendritic cell (DC) modulator in rheumatoid arthritis (RA), Rise Therapeu...
GW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER...
New GMP facility for transfection reagents of French sub-group Sartorius Stedim Biotech in Illkirch Facility equipped to support next-generation techn...
Vimseltinib is the first and only therapy with marketing authorization for the treatment of TGCT in the European Union Ono Pharmaceutical Co.,...
Proprietary process reduces development timelines from 18 months to as little as 3, eliminates reliance on traditional plastic flatware, and offers rap...
NurExone Biologic Inc., a biopharmaceutical innovator in exosome-based regenerative therapies, is pleased to announce that its U.S. subsidiary, Exo...
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being investigated to treat a wide range of solid cancers in combinati...
Parexel, a leading global clinical research organization (CRO), and Paradigm Health, a company rebuilding the clinical research ecosystem, announced a st...
Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa’s...
uLab Systems®, a leader in digital orthodontic innovation, and Biolux Technology, creator of the OrthoPulse® near-infrared (NIR) light therapy de...
Scipher Medicine, a pioneer in network-based and AI-driven precision immunology, announced a strategic collaboration with Maxymune Therapeutics, a ...
Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune d...
Booking Health, a global medical travel platform, announced the expansion of patient access to dendritic cell immunotherapy for recurrent glioblastoma, f...
© 2025 Biopharma Boardroom. All Rights Reserved.
